Cargando…
Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed?
BACKGROUND: Traditionally, prolonged courses of intravenous antibiotics have been recommended to treat Staphylococcus aureus bacteremia. However, this approach can be associated with catheter-related complications and can be costly. The purpose of our study was to describe the treatment regimens and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631417/ http://dx.doi.org/10.1093/ofid/ofx163.1700 |
_version_ | 1783269465765445632 |
---|---|
author | Dona, Daniele Hamdy, Rana F Zaoutis, Theoklis Gerber, Jeffrey S |
author_facet | Dona, Daniele Hamdy, Rana F Zaoutis, Theoklis Gerber, Jeffrey S |
author_sort | Dona, Daniele |
collection | PubMed |
description | BACKGROUND: Traditionally, prolonged courses of intravenous antibiotics have been recommended to treat Staphylococcus aureus bacteremia. However, this approach can be associated with catheter-related complications and can be costly. The purpose of our study was to describe the treatment regimens and outcomes of children with S. aureus bacteremia. METHODS: We conducted a single center retrospective cohort study over a 5-year period including all children ≤18 years hospitalized with S. aureus bacteremia. We excluded children with polymicrobial bloodstream infections and with incomplete records. We compared baseline characteristics and clinical outcomes between those treated with intravenous (IV)-only antibiotics, >7 days IV course followed by oral antibiotics (LongIV+PO) and <7 days IV course followed by oral switch (ShortIV+PO), using Pearson’s chi-squared test to compare dichotomous variables. RESULTS: We identified 314 episodes of S. aureus bacteremia. Most (59.9%) received IV-only regimen, 61/314 (19.4%) were treated with LongIV+PO and 65/314 (20.7%) treated with ShortIV+PO. The mean age was 4.2 years for those treated with the IV-only regimen compared with 6.7 years and 8.3 years for children treated with LongIV+PO and ShortIV+PO regimens respectively. Catheter-related infections were more frequently treated with IV-only (85% IV-only; 9% LongIV+PO; 6% ShortIV+PO), as was pneumonia (61% IV-only; 28% LongIV+PO; 11% ShortIV+PO), whereas musculoskeletal infections (25.6% IV-only; 29.5% LongIV+PO; 44.9% ShortIV+PO), and skin/soft-tissue infections (35% IV-only; 27.5% LongIV+PO; 37.5% ShortIV+PO) were more commonly treated with a short IV course. Recurrence of infection within 30 days occurred in 5/176 (2.8%) of those in the IV-only regimen, in 1/60 (1.7%) who received the LongIV+PO regimen, and in 2/63 (3.2%) of those in the ShortIV+PO regimen (P = 0.85). CONCLUSION: In this cohort study of children with S. aureus bacteremia, most were treated with IV-only course, while 40% were transitioned to an oral regimen after either a short or long IV course. Infections arising from a skin/soft tissue or musculoskeletal source were more likely to be transitioned to a PO regimen. Recurrence rates in the antibiotic route regimen groups were similar. DISCLOSURES: T. Zaoutis, Astellas: Consultant, Consulting fee; Merck: Grant Investigator, Research grant; nabriva: Consultant, Consulting fee |
format | Online Article Text |
id | pubmed-5631417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56314172017-11-07 Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? Dona, Daniele Hamdy, Rana F Zaoutis, Theoklis Gerber, Jeffrey S Open Forum Infect Dis Abstracts BACKGROUND: Traditionally, prolonged courses of intravenous antibiotics have been recommended to treat Staphylococcus aureus bacteremia. However, this approach can be associated with catheter-related complications and can be costly. The purpose of our study was to describe the treatment regimens and outcomes of children with S. aureus bacteremia. METHODS: We conducted a single center retrospective cohort study over a 5-year period including all children ≤18 years hospitalized with S. aureus bacteremia. We excluded children with polymicrobial bloodstream infections and with incomplete records. We compared baseline characteristics and clinical outcomes between those treated with intravenous (IV)-only antibiotics, >7 days IV course followed by oral antibiotics (LongIV+PO) and <7 days IV course followed by oral switch (ShortIV+PO), using Pearson’s chi-squared test to compare dichotomous variables. RESULTS: We identified 314 episodes of S. aureus bacteremia. Most (59.9%) received IV-only regimen, 61/314 (19.4%) were treated with LongIV+PO and 65/314 (20.7%) treated with ShortIV+PO. The mean age was 4.2 years for those treated with the IV-only regimen compared with 6.7 years and 8.3 years for children treated with LongIV+PO and ShortIV+PO regimens respectively. Catheter-related infections were more frequently treated with IV-only (85% IV-only; 9% LongIV+PO; 6% ShortIV+PO), as was pneumonia (61% IV-only; 28% LongIV+PO; 11% ShortIV+PO), whereas musculoskeletal infections (25.6% IV-only; 29.5% LongIV+PO; 44.9% ShortIV+PO), and skin/soft-tissue infections (35% IV-only; 27.5% LongIV+PO; 37.5% ShortIV+PO) were more commonly treated with a short IV course. Recurrence of infection within 30 days occurred in 5/176 (2.8%) of those in the IV-only regimen, in 1/60 (1.7%) who received the LongIV+PO regimen, and in 2/63 (3.2%) of those in the ShortIV+PO regimen (P = 0.85). CONCLUSION: In this cohort study of children with S. aureus bacteremia, most were treated with IV-only course, while 40% were transitioned to an oral regimen after either a short or long IV course. Infections arising from a skin/soft tissue or musculoskeletal source were more likely to be transitioned to a PO regimen. Recurrence rates in the antibiotic route regimen groups were similar. DISCLOSURES: T. Zaoutis, Astellas: Consultant, Consulting fee; Merck: Grant Investigator, Research grant; nabriva: Consultant, Consulting fee Oxford University Press 2017-10-04 /pmc/articles/PMC5631417/ http://dx.doi.org/10.1093/ofid/ofx163.1700 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Dona, Daniele Hamdy, Rana F Zaoutis, Theoklis Gerber, Jeffrey S Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title | Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title_full | Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title_fullStr | Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title_full_unstemmed | Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title_short | Treatment of Staphylococcus aureus Bacteremia in Children: Is Intravenous Therapy Always Needed? |
title_sort | treatment of staphylococcus aureus bacteremia in children: is intravenous therapy always needed? |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631417/ http://dx.doi.org/10.1093/ofid/ofx163.1700 |
work_keys_str_mv | AT donadaniele treatmentofstaphylococcusaureusbacteremiainchildrenisintravenoustherapyalwaysneeded AT hamdyranaf treatmentofstaphylococcusaureusbacteremiainchildrenisintravenoustherapyalwaysneeded AT zaoutistheoklis treatmentofstaphylococcusaureusbacteremiainchildrenisintravenoustherapyalwaysneeded AT gerberjeffreys treatmentofstaphylococcusaureusbacteremiainchildrenisintravenoustherapyalwaysneeded |